MX2016011630A - Derivados de isotiazol como agonistas del gpr120 para el tratamiento de la diabetes tipo ii. - Google Patents

Derivados de isotiazol como agonistas del gpr120 para el tratamiento de la diabetes tipo ii.

Info

Publication number
MX2016011630A
MX2016011630A MX2016011630A MX2016011630A MX2016011630A MX 2016011630 A MX2016011630 A MX 2016011630A MX 2016011630 A MX2016011630 A MX 2016011630A MX 2016011630 A MX2016011630 A MX 2016011630A MX 2016011630 A MX2016011630 A MX 2016011630A
Authority
MX
Mexico
Prior art keywords
diabetes
treatment
type
gpr120 agonists
isothiazole derivatives
Prior art date
Application number
MX2016011630A
Other languages
English (en)
Other versions
MX367852B (es
Inventor
Mark R Player
Xuqing Zhang
R Illig Carl
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2016011630A publication Critical patent/MX2016011630A/es
Publication of MX367852B publication Critical patent/MX367852B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen compuestos, composiciones y métodos para tratar trastornos que son afectados por la modulación del receptor GPR120; esos compuestos se representan por la Fórmula (I) de la manera siguiente: (ver Fórmula) en donde R1, G y Q se definen en la presente descripción.
MX2016011630A 2014-03-07 2014-03-07 Derivados de isotiazol como agonistas del gpr120 para el tratamiento de la diabetes tipo ii. MX367852B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/021775 WO2015134039A1 (en) 2014-03-07 2014-03-07 Isothiazole derivatives as gpr120 agonists for the treatment of type ii diabetes

Publications (2)

Publication Number Publication Date
MX2016011630A true MX2016011630A (es) 2016-11-29
MX367852B MX367852B (es) 2019-09-09

Family

ID=50391464

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011630A MX367852B (es) 2014-03-07 2014-03-07 Derivados de isotiazol como agonistas del gpr120 para el tratamiento de la diabetes tipo ii.

Country Status (8)

Country Link
EP (2) EP3114123B1 (es)
JP (1) JP6303031B2 (es)
CN (1) CN106414434B (es)
AU (1) AU2014385276B2 (es)
CA (1) CA2941445A1 (es)
ES (2) ES2673578T3 (es)
MX (1) MX367852B (es)
WO (1) WO2015134039A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017158355A1 (en) 2016-03-15 2017-09-21 Queen Mary University Of London Method of treatment of obesity
JP6809278B2 (ja) 2017-02-17 2021-01-06 Jnc株式会社 重合性液晶化合物、重合性液晶組成物および液晶重合膜
JP2021517142A (ja) 2018-03-15 2021-07-15 アクザム ソシエタ ペル アチオニ 置換ピラゾールｆｆａ４／ｇｐｒ１２０受容体作動薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8750298A (en) * 1997-08-28 1999-03-22 Ono Pharmaceutical Co. Ltd. Peroxisome proliferator-activated receptor controllers
JP4594611B2 (ja) * 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
GB0405033D0 (en) * 2004-03-05 2004-04-07 Karobio Ab Novel pharmaceutical compositions
WO2010048207A2 (en) * 2008-10-21 2010-04-29 Metabolex, Inc. Aryl gpr120 receptor agonists and uses thereof
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
JP6336561B2 (ja) * 2013-03-14 2018-06-06 ヤンセン ファーマシューティカ エヌ．ベー． Ｉｉ型糖尿病を処置するためのｇｐｒ１２０アゴニスト

Also Published As

Publication number Publication date
EP3409671B1 (en) 2021-07-21
ES2887011T3 (es) 2021-12-21
ES2673578T3 (es) 2018-06-22
EP3409671A1 (en) 2018-12-05
JP2017507189A (ja) 2017-03-16
MX367852B (es) 2019-09-09
CN106414434A (zh) 2017-02-15
AU2014385276A1 (en) 2016-09-01
WO2015134039A1 (en) 2015-09-11
EP3114123A1 (en) 2017-01-11
AU2014385276B2 (en) 2019-01-17
EP3114123B1 (en) 2018-04-25
JP6303031B2 (ja) 2018-03-28
CN106414434B (zh) 2019-12-31
CA2941445A1 (en) 2015-09-11

Similar Documents

Publication Publication Date Title
PH12017500653A1 (en) Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
TW201613878A (en) Pyrazine GPR40 agonists for the treatment of type II diabetes
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
MY189453A (en) 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
TN2017000196A1 (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139
MX2017015980A (es) Moduladores de receptor nuclear.
PH12016501613A1 (en) Pyrazines modulators of gpr6
PH12016501393A1 (en) Substituted bicyclic heteroaryl compounds as rxr agonists
EA201591734A1 (ru) Бензоконденсированные гетероциклические производные, подходящие для использования в качестве агонистов gpr120
MX367852B (es) Derivados de isotiazol como agonistas del gpr120 para el tratamiento de la diabetes tipo ii.
TN2016000177A1 (en) P-substituted asymmetric ureas and medical uses thereof
PH12017501560A1 (en) Tetrahydropyranyl benzamide derivatives
MX2023001906A (es) Diarilureas como moduladores alostericos de cannabinoide cb1.
MX2016011629A (es) Derivados de pirrol biciclicos utiles como agonistas de gpr120.
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs

Legal Events

Date Code Title Description
FG Grant or registration